Lauren is my name, and always has been — or so I thought until one afternoon just before I turned 30. Over turkey sandwiches, my oldest sister, Missy, and I discussed what our names might have been. “Mom was going to name you Amy Beth,” I said. Missy nodded. “And how crazy is it that… Read More »
On Episode 3 of HardCore Health, Jess & I start off by discussing all of the health tech companies IPOing (Livonogo, Phreesia, Health Catalyst) and talk about what that means for the industry as a whole. Zoya discusses the newest series on THCB called, “The Health Data Goldilocks Dilemma: Sharing? Privacy? Both?”, which follows &… Read More »
Parkinson’s disease is a neurodegenerative disorder that causes symptoms such as tremors, rigidity, slowness of movement and balance problems. There is no known cure for the progressive disease, and drug treatments — often offered as a first-line treatment — do not slow the underlying neurodegeneration that characterizes the condition.1 Parkinson’s symptoms often go untreated or… Read More »
When rumors emerged nearly a year ago that Bayer might be planning to exit the animal-health business, Eli Lilly spinoff Elanco was not at the top of any market-watcher’s list of potential buyers—especially not after it became clear that several private equity players were interested in the asset. Turns out Elanco was interested, and the… Read More »